Europe

MediSapiens joins international consortium for personalized medicine

Monday, January 25, 2016

MediSapiens, a Finnish developer and provider of Bio-IT solutions for research and biomedicine, is a partner in an international consortium aiming at developing personalized medicine applications using integrated genome and other health data. The consortium was founded and is headed by the Competence Centre on Health Technologies of Estonia (CCHT) in the framework of the Competence Centre program supported via Enterprise Estonia. Along with MediSapiens and CCHT, the other consortium members are the University of Tartu Estonian Genome Center (Estonia), Tallinn University of Technology eMedicine Laboratory (Estonia), BioEximi OÜ (Estonia), Duodecim Medical Publications Ltd. (Finland) and Coimbra Genomics (Portugal).

[Read More]

UCL launches $55M technology investment fund

Wednesday, January 20, 2016

UCL is launching the UCL Technology Fund to invest £50 million ($55 million) in commercializing its research emerging over the next five years. The Fund will be used to support academics whose research has commercial potential, with funding for early stage proof-of-concept, licensing projects and new spinout companies.

[Read More]

$100M Dementia Discovery Fund launches

Wednesday, October 21, 2015

The Dementia Discovery Fund, a new initiative designed to speed up the discovery and development of new treatments for dementia, has launched after securing $100 million backing from worldwide investors. The U.K. government’s Department of Health, Alzheimer’s Research U.K. and pharmaceutical companies including Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Takeda have joined forces to support the innovative new fund.

[Read More]

goBalto complies with European trial regulations

Wednesday, October 21, 2015

San Francisco-based goBalto, a provider of cloud-based clinical study startup solutions, has announced compliance with new European regulatory directives aimed at creating an environment that is favorable for conducting clinical trials across the European Union.

[Read More]